Ablynx books success with arthritis drug study

BRUSSELS Wed Feb 13, 2013 2:03am EST

Related Topics

BRUSSELS (Reuters) - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.

"We are now investigating the various possibilities through which we can progress the development of ALX-0061, including discussions with potential partners and other paths which will allow us to maximise the value of this asset," Chief Executive Edwin Moses said in a statement on Wednesday.

Ablynx had carried out the study on 37 patients over the course of 24 weeks and said the drug was well-tolerated and showed positive results.

(Reporting by Robert-Jan Bartunek; editing by Philip Blenkinsop)

FILED UNDER:
A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article